达帕格利弗洛辛在患有全身右心室功能障碍的患者中的安全性和有效性:DAPA-SRV试验
Mathieu Albertini1, Victor Waldmann1, Pauline David1
1Centre de référence des Malformations Cardiaques Congénitales Complexes, M3C. Adult Congenital Heart Disease Unit Hôpital Européen Georges Pompidou, APHP, Paris Descartes University. Centre de Recherche Cardiovasculaire de Paris, INSERM U970 Paris France.
Journal of the American Heart Association
|May 29, 2025
概括
达帕格利弗洛辛改善了系统右心室 (sRV) 功能障碍患者的运动能力和生活质量. 这项研究表明,达帕格利弗洛辛是SRV心力衰竭的安全有效治疗选择.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 对于患有全身右心室 (sRV) 的成年人来说,心力衰竭具有显著的死亡风险.
- 达帕格利弗洛辛已被确立用于获得的心脏病,但其在sRV功能障碍中的有效性尚未研究.
- 这项研究解决了关于达帕格利弗洛辛对SRV患者影响的知识差距.
研究的目的:
- 评估在患有症状sRV功能障碍的患者中达帕格利弗洛辛的安全性和有效性.
- 评估功能能力,心脏生物标志物和生活质量的变化.
主要方法:
- 从2023年2月到2024年2月进行了一项前性,观察性,单中心研究.
- 纳入了在医疗治疗中出现SRV功能障碍的症状患者 (NYHA类≥2).
- 主要终点是6分钟步行距离 (6MWD);次要终点包括NT-proBNP,KCCQ-12,NYHA类,心室功能和副作用.
主要成果:
- 包括32名患有各种形式先天性心脏病的患者 (平均年龄为48岁).
- 在6个月后,在6MWD (P=0.04),生活质量 (P<0.001) 和sRV功能 (P=0.02) 中观察到显著改善.
- 没有报告与治疗相关的显著副作用.
结论:
- 达帕格利弗洛辛在sRV功能障碍的症状患者中显示出功能益处和有利的安全概况.
- 这些发现支持通过更大的随机对照试验进一步调查.
- 达帕格利弗洛辛 (Dapagliflozin) 是治疗SRV心力衰竭的潜在治疗选择.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
271
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
271
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
526
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
526
01:29Heart Failure II: Pathophysiology
59
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
59